Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Versarien in exclusive talks to sell off remaining assets, shares sink

(Sharecast News) - Versarien's share price tanked on Friday after the advanced engineering materials group announced the proposed disposal of its remaining assets to an unnamed party. The company, which previously announced it had been "progressing discussions" regarding offers for the business and its assets, is now in advanced talks with a UK-listed company, a statement said on Friday.

Versarien said it has now signed a non-binding agreement with the third party for the disposal of its "remaining material assets and subsidiaries", and has entered into a period of exclusivity until 30 November.

Under the terms of the offer, the acquirer will purchase Versarien's shares in Total Carbide and Gnanomat, together with the patent and trademark portfolio held by Versarien and related graphene production equipment.

The acquirer will pay £100,000 in cash and £100,000 in shares, as well as taking on a £5.7m loan from Innovate UK Loans.

In the meantime, Versarien said it has enough cash to last it until the end of the exclusivity period.

"If the transaction is successfully completed, the company would not have any operations and would become an AIM Rule 15 cash shell, at which point it would seek to settle its remaining liabilities and look for reverse takeover opportunities," the company said.

Shares were down 22% at 0.011p by 1209 GMT, having now dropped more than 70% since the start of 2025.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.